GLP 1s
A topic on our watch list — we track its coverage across 7 domains, including Biotech Pharma, Chinese Overcapacity and Defense Tech Startups.
Coverage of GLP 1s is newly on the wire: 8 signals on the latest tracked day, level with its three-week baseline of 8, across 7 domains. That makes it the #310 most-covered of the 337 concerns we track.
If GLP 1s matters to your work, it just crossed our flagging thresholds — early and thin history, so watch whether the next few days confirm the move or fade it.
What’s changed
- Hershey CEO Kirk Tanner on GLP-1s, AI, and keeping an iconic brand relevant · Fast Company · 2026-10-01
- EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s · Clinical Trials Arena · 2026-10-01
- STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more · STAT News — All Content · 2026-09-29
- STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’ · STAT News — All Content · 2026-09-28
- GLP-1s linked to nutritional deficiencies in children · The Medical News · 2026-09-24
- Compounder Empower receives FDA warning letter over GLP-1s · Endpoints News · 2026-09-23
What the reporting says
It shows up alongside GLP-1 (53), FDA (21), Eli Lilly (16), Novo Nordisk (8), Americans (11), AI (10), Mounjaro (10), Drug Administration (8).
Two steps out: Zepbound (through GLP-1, 33 shared stories on the weaker link); Denmark (through GLP-1, 32 shared stories on the weaker link); China (through GLP-1, 26 shared stories on the weaker link); Clinical Trial (through GLP-1, 25 shared stories on the weaker link).
Tracked since Apr 6, with coverage on 20 separate days — concentrated in Auto and Biotech Pharma.